Abstract: Compounds of the formula: ##STR1## wherein the substituents are as defined herein, and enantiomers, diastereomers, racemates and salts with pharmaceutically acceptable bases, antagonize LTD.sub.4 action and thus, are useful in treating bronchial asthma, pulmonary anaphylaxis, cystic fibrosis, chronic bronchitis, bronchiectasis, respiratory distress syndrome and pulmonary oedema.

Abstract: Compounds of the formula: ##STR1## wherein the substituents are as described in the specification, antagonize LTD.sub.4 action and thus, are useful in treating bronchial asthma, pulmonary anaphylaxis, cystic fibrosis, chronic bronchitis, bronchiectasis, respiratory distress syndrome and pulmonary oedema.

Abstract: The invention relates to compounds of the formula: ##STR1## wherein R is hydrogen or lower alkyl, R.sub.1, R.sub.2, R.sub.3 and R.sub.4, independently, are hydrogen, lower alkyl, lower alkenyl, cycloalkyl or phenyl unsubstituted or substituted by up to 3 substituents independently selected from lower alkyl, lower alkoxy or halogen, or R.sub.1 and R.sub.2 taken together with the carbon atom are alkylene of 2 to 5 carbon atoms unsubstituted or substituted by lower alkyl, and n is an integer of from 0 to 3,and, when R.sub.1 is different from R.sub.2 and/or when R.sub.3 is different from R.sub.4, enantiomers, diastereomers and racemates thereof and, when R is hydrogen, salts thereof with pharmaceutically acceptable bases.The compounds of formula I and, when R is hydrogen, pharmaceutically exceptable salts thereof are useful as bronchopulmonary agents, for example, in the relief of asthma and allergic reactions.

Abstract: Disclosed are compounds of the formula ##STR1## wherein: R.sup.1 and R.sub.2 may be either the same or different and each is hydrogen or lower alkyl;and wherein R.sup.3 and R.sup.4 may be either the same or different and each is hydrogen, halogen, or lower alkyl, with the proviso that R.sup.3 and R.sup.4 cannot both be hydrogen.These compounds are useful as anticonvulsant or anxiolytic agents.

Abstract: A multistep process is presented for the preparation of imidazobenzodiazepines of the formula ##STR1## wherein X and Y are selected from the group consisting of hydrogen, halogen and trifluoromethyl.Also presented are novel intermediates utilized in the process.The end products are useful as sedatives, anxiolytics, muscle relaxants and anticonvulsants.The end products are especially useful in intravenous compositions for use in preoperative anesthesia.

Abstract: Novel intermediates of the formula ##STR1## wherein X and Y are hydrogen, halogen or trifluoromethyl and R.sub.1 is hydrogen or lower alkyl are presented.Also disclosed is a process leading to the intermediates and their conversion to imidazobenzodiazepines, compounds of pharmacological activity.

Abstract: Novel intermediates of the formula ##STR1## wherein X and Y are hydrogen, halogen or trifluoromethyl and R.sub.1 is hydrogen or lower alkyl are presented.Also disclosed is a process leading to the intermediates and their conversion to imidazobenzodiazepines, compounds of pharmacological activity.

Abstract: A multistep process is presented for the preparation of imidazobenzodiazepines of the formula ##STR1## wherein X and Y are selected from the group consisting of hydrogen, halogen and trifluoromethyl.Also presented are novel intermediates utilized in the process.The end products are useful as sedatives, anxiolytics, muscle relaxants and anticonvulsants.The end products are especially useful in intravenous compositions for use in preoperative anesthesia.